Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 3/20 | 0.37 |
| ▸ | BTK | Q06187 | 3/20 | 0.37 |
| ▸ | CA1 | P00915 | 3/20 | 0.33 |
| ▸ | CA2 | P00918 | 3/20 | 0.33 |
| ▸ | CA9 | Q16790 | 3/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
| ▸ | CA3 | P07451 | 1/20 | 0.33 |
| ▸ | CA4 | P22748 | 1/20 | 0.33 |
| ▸ | CA6 | P23280 | 1/20 | 0.33 |
| ▸ | CA5A | P35218 | 1/20 | 0.33 |
| ▸ | CA7 | P43166 | 1/20 | 0.33 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.33 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.33 |
| ▸ | LPL | P06858 | 4/20 | 0.32 |
| ▸ | LIPG | Q9Y5X9 | 4/20 | 0.32 |
| ▸ | CXCR2 | P25025 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17236448 | 0.86 | LPL (0.38) | JAK2BTKCA1CA2CA9 | |
| SCHEMBL17660374 | 0.83 | JAK2 (0.41) | JAK2BTKLPLLIPGCXCR2 | |
| SCHEMBL21928363 | 0.82 | JAK2 (0.34) | JAK2BTKCA1CA2CA9 | |
| SCHEMBL21998954 | 0.80 | ADRA1A (0.30) | — | |
| SCHEMBL29288003 | 0.78 | JAK2 (0.38) | JAK2BTKLPLLIPGCXCR2 | |
| SCHEMBL20540433 | 0.78 | JAK2 (0.39) | JAK2BTKLPLLIPGCXCR2 | |
| SCHEMBL15000450 | 0.78 | PDCD1 (0.42) | JAK2BTKLPLLIPGCXCR2 | |
| SCHEMBL29712932 | 0.78 | PDCD1 (0.42) | JAK2BTKLPLLIPGCXCR2 | |
| SCHEMBL31381519 | 0.77 | JAK2 (0.39) | JAK2BTKCA1CA2CA9 | |
| SCHEMBL11927624 | 0.77 | LPL (0.44) | JAK2BTKCA1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11021486-B2 | Coumarin-like cyclic compound as MEK inhibitor and use thereof | CSTONE PHARMACEUTICALS (KY) | 2021-06-01 | — | — | US | disclosed |
| EP-3643308-B1 | COUMARIN-LIKE CYCLIC COMPOUND AS MEK INHIBITOR AND USE THEREOF | CSTONE PHARMACEUTICALS (KY) | 2021-05-19 | — | — | EP | disclosed |
| US-20200148695-A1 | COUMARIN-LIKE CYCLIC COMPOUND AS MEK INHIBITOR AND USE THEREOF | CSTONE PHARMACEUTICALS (KY) | 2020-05-14 | — | — | US | disclosed |
| EP-3643308-A1 | COUMARIN-LIKE CYCLIC COMPOUND AS MEK INHIBITOR AND USE THEREOF | CSTONE PHARMACEUTICALS (KY) | 2020-04-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11021486-B2 | Coumarin-like cyclic compound as MEK inhibitor and use thereof | MAP3K11, MAP3K15, MAP3K20 | JAK2 110/4885BTK 67/4885CA1 4400/4885 |
| US-20200148695-A1 | COUMARIN-LIKE CYCLIC COMPOUND AS MEK INHIBITOR AND USE THEREOF | MAP3K11, MAP3K15, MAP3K20 | JAK2 110/4885BTK 67/4885CA1 4400/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.